Crescent Biopharma

Crescent Biopharma's vision is to build a world-leading oncology company bringing the next wave of therapies for cancer patients. The company's clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors.